Overview
Overview
Prostamax is a synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Pro / KEDP) derived from prostate tissue peptide complex research[1][2]. Short peptides of this class have been studied for their ability to modulate gene expression through epigenetic interactions with chromatin and histones[3][4]. This educational protocol presents a once‑daily intramuscular approach using a practical dilution for clear insulin‑syringe measurements. Reconstitute: Add 2.0 mL bacteriostatic water → 10 mg/mL concent
- Category
- Longevity
- Routes
- intramuscular
Mechanism
Prostamax
Mechanism of action
Mechanism of action
Prostamax (KEDP) belongs to the class of short bioregulatory peptides studied by Khavinson and colleagues. These tetrapeptides are proposed to modulate gene expression through epigenetic mechanisms, interacting with chromatin structure and histone proteins [3] [4] . In aged human lymphocytes, KEDP has been observed to cause pericentromeric chromatin decondensation, potentially reactivating suppressed genes [3] . Preclinical rat models of prostatitis showed that IM administration of KEDP reduced inflammatory markers and helped prevent fibrotic changes in prostate tissue [1] [2] .
Key research findings
- 01
Chemical identity (in vitro / literature): In the peer-reviewed record, Prostamax is described as a synthetic short-chain oligopeptide bioregulator with the sequence Lys-Glu-Asp-Pro (KEDP), one of the Khavinson-class 'cytogen' short peptides developed at the St. Petersburg Institute of Bioregulation and Gerontology (PubMed: PMID 23221144; review context PMID 12374906).
- 02
Epigenetic/chromatin observations (in vitro, human cells ex vivo): In cultured lymphocytes/leukocytes from elderly donors (~75-88 years), Prostamax was reported to activate ribosomal genes and induce decondensation of densely packed heterochromatin ('deheterochromatinization'), interpreted by the authors as relaxation of age-condensed chromatin (PubMed: PMID 15085253, DOI 10.1023/b:bebm.0000024393.40560.05; PMID 23221144). These are exploratory cellular observations, not clinical outcomes.
- 03
Biophysical chromatin measurements (in vitro): Differential scanning microcalorimetry of human lymphocyte chromatin reported small Prostamax-associated shifts in thermal denaturation endotherms, consistent with partial relaxation of higher-order chromatin packing (PubMed: PMID 15612551, Biofizika 2004; PMID 19359734, 2009).
- 04
Tissue-specific stimulation (animal model / ex vivo organotypic culture): In explant cultures of tissues from young and aged rats, Prostamax (alongside cardiogen, bronchogen, pancragen) reportedly stimulated explant outgrowth at ~0.05 ng/ml with preferential activity in the corresponding (prostate) tissue, the empirical basis for the proposed 'tissue-specificity' of these peptides (PubMed: PMID 17152728, Adv Gerontol 2006).
- 05
Maturity / honesty note (research base): No randomized controlled human trials of synthetic Prostamax (KEDP) are indexed in PubMed; the indexed evidence is a small set of in-vitro-dominant studies from a narrow group of Russian/Georgian investigators. A separate, larger literature exists for the natural bovine-prostate polypeptide complex Prostatilen (a distinct 'cytomedine' preparation), but those findings should not be assumed to transfer to the synthetic peptide.
Primary source: Based on articles retrieved from PubMed, the peer-reviewed base for synthetic Prostamax (Lys-Glu-Asp-Pro) is limited and early-stage: roughly five indexed primary papers, predominantly small in vitro studies of chromatin/epigenetic changes in cultured lymphocytes from elderly human donors plus one rat organotypic tissue-culture study, largely from a narrow set of Russian and Georgian groups. There are no randomized controlled human trials of the synthetic peptide indexed in PubMed, so findings should be read as exploratory and the larger literature on the related but distinct natural prostate complex Prostatilen does not directly validate Prostamax.
Researched Effects
Researched benefits
Areas of active research and investigation. Results may vary and are based on preclinical or early clinical data.
In rat prostatitis models, IM KEDP administration reduced inflammation and supported tissue normalization over treatment periods of 15–60 days[1].
Studies in benign prostatic hyperplasia (BPH) models showed favorable effects on prostate weight and histological parameters[2].
Short bioregulatory peptides of this class generally show favorable tolerability profiles in preclinical work[4].
Potential for mild injection‑site reactions (redness, tenderness) as with any IM administration; rotate sites to minimize.
Note: Human clinical trial data are not yet published; dosing is extrapolated from animal models.
Protocol Reference
Protocol reference
Commonly cited research range: 500–1000 mcg, daily.
Reference figures reported in the research literature — not a dosing recommendation. For interactive vial math and scheduling, see the Calculator and Schedule tabs.
Cited protocol & reconstitution guide
Source-backed reference fields by phase, including any volume fields authored in the cited guide.
Weeks 1–2
500 mcg (0.5 mg)
Weeks 3–4
750 mcg (0.75 mg)
Weeks 5–8
1,000 mcg (1 mg)
Weeks 9–12 (optional extension)
1,000 mcg (1 mg)
| Phase | Reference amount | Units / volume |
|---|---|---|
| Weeks 1–2 | 500 mcg (0.5 mg) | 5 units (0.05 mL) |
| Weeks 3–4 | 750 mcg (0.75 mg) | 7.5 units (0.075 mL) |
| Weeks 5–8 | 1,000 mcg (1 mg) | 10 units (0.10 mL) |
| Weeks 9–12 (optional extension) | 1,000 mcg (1 mg) | 10 units (0.10 mL) |
Storage & Handling
Storage requirements(typical for most peptides)
Can be stored for extended periods. Protect from moisture.
Store in refrigerator door. Never freeze after reconstitution.
Label vials with reconstitution date. Discard if cloudy.
Reconstitution steps
- 01🌡️Draw 2.0 mL bacteriostatic water with a sterile syringe.
- 02🧴Inject slowly down the vial wall; avoid foaming.
- 03💉Gently swirl/roll until dissolved (do not shake).
- 04💧Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 2 weeks.
- 05🔄Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Additional storage notes
Refrigerate at 4 °C (39.2 °F) in dry, dark conditions.
Store at −20 °C (−4 °F) for extended stability.
Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~2 weeks and avoid freeze–thaw cycles .
Allow vials to reach room temperature before opening to reduce condensation uptake.
Clinical Evidence
Clinical evidence
Preclinical research describes tissue-normalizing peptide activity; human data are limited.
Based on articles retrieved from PubMed, the peer-reviewed base for synthetic Prostamax (Lys-Glu-Asp-Pro) is limited and early-stage: roughly five indexed primary papers, predominantly small in vitro studies of chromatin/epigenetic changes in cultured lymphocytes from elderly human donors plus one rat organotypic tissue-culture study, largely from a narrow set of Russian and Georgian groups. There are no randomized controlled human trials of the synthetic peptide indexed in PubMed, so findings should be read as exploratory and the larger literature on the related but distinct natural prostate complex Prostatilen does not directly validate Prostamax.
- 01Chemical identity (in vitro / literature): In the peer-reviewed record, Prostamax is described as a synthetic short-chain oligopeptide bioregulator with the sequence Lys-Glu-Asp-Pro (KEDP), one of the Khavinson-class 'cytogen' short peptides developed at the St. Petersburg Institute of Bioregulation and Gerontology (PubMed: PMID 23221144; review context PMID 12374906).
- 02Epigenetic/chromatin observations (in vitro, human cells ex vivo): In cultured lymphocytes/leukocytes from elderly donors (~75-88 years), Prostamax was reported to activate ribosomal genes and induce decondensation of densely packed heterochromatin ('deheterochromatinization'), interpreted by the authors as relaxation of age-condensed chromatin (PubMed: PMID 15085253, DOI 10.1023/b:bebm.0000024393.40560.05; PMID 23221144). These are exploratory cellular observations, not clinical outcomes.
- 03Biophysical chromatin measurements (in vitro): Differential scanning microcalorimetry of human lymphocyte chromatin reported small Prostamax-associated shifts in thermal denaturation endotherms, consistent with partial relaxation of higher-order chromatin packing (PubMed: PMID 15612551, Biofizika 2004; PMID 19359734, 2009).
- 04Tissue-specific stimulation (animal model / ex vivo organotypic culture): In explant cultures of tissues from young and aged rats, Prostamax (alongside cardiogen, bronchogen, pancragen) reportedly stimulated explant outgrowth at ~0.05 ng/ml with preferential activity in the corresponding (prostate) tissue, the empirical basis for the proposed 'tissue-specificity' of these peptides (PubMed: PMID 17152728, Adv Gerontol 2006).
- 05Maturity / honesty note (research base): No randomized controlled human trials of synthetic Prostamax (KEDP) are indexed in PubMed; the indexed evidence is a small set of in-vitro-dominant studies from a narrow group of Russian/Georgian investigators. A separate, larger literature exists for the natural bovine-prostate polypeptide complex Prostatilen (a distinct 'cytomedine' preparation), but those findings should not be assumed to transfer to the synthetic peptide.
Evidence maturity varies by compound; much peptide research is preclinical (in vitro or animal-model). Where human data are limited, findings should be read as research observations, not clinical conclusions.
References
Literature references
Published research articles and sources related to Prostamax.
- 01Modern Research in Inflammation (2013) — Experimental study of Prostamax efficiency in chronic aseptic prostatitis therapy and complications View Sourceet al. (2013)
- 02Modern Research in Inflammation (2014) — Experimental study of tetrapeptide Lysyl-Glutamyl-Aspartyl-Proline in benign prostatic hyperplasia model View Sourceet al. (2014)
- 03Bulletin of Experimental Biology and Medicine (2004) — Effects of short peptides on lymphocyte chromatin in senile subjects (KEDP and chromatin decondensation) View Sourceet al. (2004)
- 04Stem Cell Reviews and Reports (2020) — Peptide regulation of cell differentiation: epigenetic mechanisms of short bioregulatory peptides View Sourceet al. (2020)
- 05CDC — Vaccine administration: Intramuscular (IM) injection guidelines for adults View Source
- 06CDC (Subcut Injection PDF) — Technique diagram and site guidance for subcutaneous injections View Source
- 07CDC — Vaccine administration: During vaccination (aspiration guidance, aseptic technique) View Source
- 08NIBSC (MHRA) — Peptide handling, dissolution, and storage best practices View Source
- 09NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) View Source
- 10CDC — General best practices for immunization: injection technique and safety View Source
- 11Subcutaneous Drug Injection Review (PMC) — Pharmacologic considerations of the subcutaneous route View Source
- 12Pure Lab Peptides — Prostamax (20 mg) product page (quality and batch documentation) View Source
Research Considerations
Research considerations
Research Use Only - not for human or veterinary therapeutic use. Current evidence is limited to in vitro and/or animal-model research; human data are minimal or absent. Consult a licensed healthcare professional for any clinical decisions.
Factors noted in the research literature; not patient-specific medical advice.
Regulatory Status
Regulatory status
RUO
Comparisons
Comparisons
| Compound | Mechanism | Route | Status |
|---|---|---|---|
| Prostamaxthis | A synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Pro) derived from prostate peptide-complex research, studied for tissue-specific regulatory effects on prostate tissue. | intramuscular | Investigational / RUO |
| SNAP-8 | A synthetic acetylated octapeptide (an extended Argireline analog) studied for topical reduction of muscle contraction by interfering with SNARE-complex formation at the neuromuscular junction. | subcutaneous | Investigational / RUO |
| SS-31 | A mitochondria-targeted tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing electron-transport-chain organization and reducing reactive oxygen species. | subcutaneous | Investigational / RUO |
| Testagen | A synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Gly) studied for modulation of endocrine function, particularly pituitary-gonadal regulatory pathways. | subcutaneous | Investigational / RUO |
| Vesugen (Lys-Glu-Asp) | A synthetic tripeptide bioregulator (Lys-Glu-Asp) studied for gene-regulatory support of vascular endothelial tissue. | subcutaneous | Investigational / RUO |
| PT-141 | A cyclic heptapeptide melanocortin receptor agonist (MC3R/MC4R), an active metabolite of melanotan II, acting on central melanocortin pathways studied for modulation of sexual-response signaling. | subcutaneous | Investigational / RUO |
| Retatrutide | An investigational triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors, combining appetite regulation, insulinotropic activity, and increased energy expenditure. | subcutaneous | Investigational / RUO |
Attributes shown for research comparison only; not a statement of efficacy or therapeutic equivalence.
FAQ
Frequently asked questions
According to PubMed-indexed literature, Prostamax is a synthetic short-chain peptide bioregulator with the sequence Lys-Glu-Asp-Pro (KEDP), one of the Khavinson-class 'cytogen' peptides developed at the St. Petersburg Institute of Bioregulation and Gerontology and studied in the context of cellular aging and tissue-specific regulation. It is a Research Use Only compound.
The small published record focuses mainly on epigenetic/chromatin observations in cultured lymphocytes from elderly donors (chromatin decondensation and ribosomal-gene activation) and on tissue-specific stimulation of rat tissue explants in organotypic culture. These are exploratory laboratory endpoints, not clinical outcomes, and no therapeutic effect is established.
No randomized controlled human trials of the synthetic peptide (KEDP) are indexed in PubMed. Some work used lymphocytes from elderly subjects, but that is ex vivo cell-culture research rather than clinical efficacy testing. The evidence is best described as limited peer-reviewed data.
In the literature, Prostatilen denotes a natural polypeptide complex extracted from prostate tissue (a 'cytomedine'), whereas Prostamax is described as a defined synthetic peptide (KEDP, a 'cytogen'). They are conceptually related but are distinct preparations, so research on Prostatilen should not be assumed to apply to Prostamax.
Proposed mechanisms center on epigenetic regulation: short Lys/Glu/Asp-containing peptides are hypothesized to interact with chromatin and influence gene-expression accessibility (for example, chromatin decondensation), framed within Khavinson's 'peptide theory of aging.' These remain hypotheses drawn from small studies rather than established pharmacology.
There is no established or medically endorsed human dosing; research-reported amounts vary, and in vitro studies used nanogram-per-milliliter culture concentrations that do not translate to human use. For any protocol parameters, consult the specific cited study or a protocol reference. This is not medical advice.
Published Prostamax studies are small and mechanistic (chromatin and tissue-culture endpoints) and do not constitute a safety dataset; the observed effects in research are limited to the cellular changes reported in vitro, and no rigorous human tolerability data specific to the synthetic peptide are indexed. It is Research Use Only and not for human use.
Research-use notice
Research Use Only. This educational content and calculation support is intended for private research documentation. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.